|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY
Division of Cancer Research, National Health Research Institutes (C.-C.K., J.-F.L., J.-Y.C.) and Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center (J.-Y.C.), Taipei, Taiwan, Republic of China
Two camptothecin-resistant cell lines, CPT30 and KB100, were established and characterized previously in our laboratory. Because enhanced sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and decreased expression of O6-methylguanine-DNA methyltransferase (MGMT) protein were observed in these lines, we hypothesized that MGMT may be a determinant of cytotoxicity associated with camptothecin-derived DNA topoisomerase I inhibitors (CPTs). We used the Tet-On system to induce expression of MGMT in Chinese hamster ovary (CHO) cells and RNA interference to knock down MGMT expression in human nasopharyngeal carcinoma HONE-1 cells in order to identify any correlations between MGMT expression and CPTs cytotoxicity. CHO-derived Tet-On-inducible cells (S12+) showed MGMT overexpression and statistically significant more resistance to BCNU, camptothecin, 7-ethyl-10-hydrocamptothecin (SN38), and topotecan than parental CHO cells (p < 0.05), but there was less resistance to CPTs than to BCNU. Knockdown of MGMT expression with small interfering RNA in HONE-1 cells conferred increased sensitivity to BCNU and CPTs compared with mock control. Furthermore, alteration of MGMT expression coincides with CPT-induced cell death and poly(ADP-ribose) polymerase cleavage. There were no differences in protein levels and catalytic activity of topoisomerase I between MGMT-proficient and MGMT-deficient cells from the Tet-On-inducible and small interfering RNA (siRNA) systems. Resistance to CPTs coincided with decreased amounts of protein-linked DNA breaks generated by CPTs in MGMT-proficient cells and vice versa in MGMT-deficient cells. Our data indicate that MGMT can modulate cytotoxicity of CPT-derived topoisomerase I inhibitors.
Address correspondence to: Dr. Jang-Yang Chang, Division of Cancer Research, National Health Research Institutes, 7th Floor, 161, Section 6, Min-Chuan East Road, Taipei 114, Taiwan, Republic of China. E-mail: jychang{at}nhri.org.tw
This article has been cited by other articles:
![]() |
L.-C. Ma, C.-C. Kuo, J.-F. Liu, L.-T. Chen, and J.-Y. Chang Transcriptional Repression of O6-Methylguanine DNA Methyltransferase Gene Rendering Cells Hypersensitive to N,N'-Bis(2-chloroethyl)-N-nitrosurea in Camptothecin-Resistant Cells Mol. Pharmacol., August 1, 2008; 74(2): 517 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Verbeek, T. D. Southgate, D. E. Gilham, and G. P. Margison O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy Br. Med. Bull., March 1, 2008; 85(1): 17 - 33. [Abstract] [Full Text] [PDF] |
||||